Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Landau

Showing results (171-180 of 184) with videos related to

Pageof 19
Sort By:
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
Transplantation and Cellular Therapy|March 17, 2021
Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent WavesMariam T Nawas, Gunjan L Shah, Darren R Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyAnita D'Souza, Angela Dispenzieri, Baldeep Wirk, et al.
Cancer|August 30, 2022
A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantationMichael Scordo, Gunjan L Shah, Peter A Adintori, et al.
Nature Reviews. Nephrology|December 9, 2025
The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupAmanda DeMauro Renaghan, Marlies Ostermann, Claudio Ronco, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Older patients with myeloma derive similar benefit from autologous transplantationManish Sharma, Mei-Jie Zhang, Xiaobo Zhong, et al.
JAMA Oncology|April 15, 2021
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical TrialOla Landgren, Malin Hultcrantz, Benjamin Diamond, et al.
Nature Communications|July 19, 2020
Accelerated single cell seeding in relapsed multiple myelomaHeather J Landau, Venkata Yellapantula, Benjamin T Diamond, et al.
Pageof 19

Showing results (171-180 of 184) with videos related to

Sort By:
Pageof 19
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
Transplantation and Cellular Therapy|March 17, 2021
Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent WavesMariam T Nawas, Gunjan L Shah, Darren R Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyAnita D'Souza, Angela Dispenzieri, Baldeep Wirk, et al.
Cancer|August 30, 2022
A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantationMichael Scordo, Gunjan L Shah, Peter A Adintori, et al.
Nature Reviews. Nephrology|December 9, 2025
The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupAmanda DeMauro Renaghan, Marlies Ostermann, Claudio Ronco, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Older patients with myeloma derive similar benefit from autologous transplantationManish Sharma, Mei-Jie Zhang, Xiaobo Zhong, et al.
JAMA Oncology|April 15, 2021
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical TrialOla Landgren, Malin Hultcrantz, Benjamin Diamond, et al.
Nature Communications|July 19, 2020
Accelerated single cell seeding in relapsed multiple myelomaHeather J Landau, Venkata Yellapantula, Benjamin T Diamond, et al.
Pageof 19